• Return to Headlines

Recent 52-Week Low Surpassed in Shares of Immunogen Inc (IMGN)

By Nick Russo

Shares of Immunogen Inc (NASDAQ:IMGN) traded at a new 52-week low today of $1.90. Approximately 571,000 shares have changed hands today, as compared to an average 30-day volume of 3.3 million shares.

In the past 52 weeks, Immunogen Inc share prices have been bracketed by a current low of $1.90 and a high of $13.41 and are now at $1.90. The 200-day and 50-day moving averages have moved 2.47% lower and 0.14% lower over the past week, respectively.

Immunogen Inc has overhead space with shares priced $1.90, or 85.4% below the average consensus analyst price target of $13.00. Immunogen Inc shares should first meet resistance at the 50-day moving average (MA) of $2.66 and find additional resistance at the 200-day MA of $5.68.

ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.

SmarTrend is monitoring the recent change of momentum in Immunogen Inc. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Immunogen Inc in search of a potential trend change.

Keywords: 52 week high/lows immunogen inc

Ticker(s): IMGN